Global Xerostomia (Dry Mouth Disease) Therapeutics Market Overview (2022-2027)
• Historical Market Size (2021): US$ 683.45 Million
• Forecast CAGR (2022-2027): 3.75%
• Forecast Market Size (2027): US$ 862.79 Million

The global xerostomia (dry mouth disease) therapeutics market size reached US$ 683.45 Million in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 862.79 Million by 2027, exhibiting a growth rate (CAGR) of 3.75% during 2022-2027.

What is a xerostomia (dry mouth disease) therapeutics market ?

Xerostomia, or dry mouth, represents symptoms or sensations of oral dryness that are generally caused, on account of a decrease in the amount of saliva. This condition is triggered by the adverse effects of radioactivity in the neck and head, increasing consumption of antianxiety drugs, dehydration, diabetes, Alzheimer’s disorder, etc.

It can be treated with the support of salivary pens or stimulants, artificial saliva, prescribed medications, and home remedies, including sipping water and moisturizing lips. These treatments alleviate discomfort, prevent severe complications, fix taste disorders, mitigate bad breath and taste disorders, etc. As a result, xerostomia therapeutics are used across numerous hospitals and clinics to deal with decreased salivary gland function.

Request For Sample Report: https://www.imarcgroup.com/xerostomia-therapeutics-market/requestsample

Covid-19 Impact:

We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.

What are the major market drivers in the xerostomia (dry mouth disease) therapeutics Market: 

The growing incidences of dry mouth, especially among the geriatric population, owing to medicine side-effects of radiotherapy and chemotherapy and the inflating need for dry mouth relief products, are among the key factors stimulating the xerostomia (dry mouth disease) therapeutics market.

Moreover, the increasing utilization of several prescription-based toothpastes, vitamin gummies, medicines, etc., for treating Sjogren’s syndrome, Alzheimer’s diseases, human immunodeficiency virus (HIV), etc., that cause xerostomia is acting as another significant growth-inducing factor.

Besides this, the rising consumer awareness towards the early diagnosis of xerostomia, continuous enhancements in healthcare expenditures, and the development of diverse diagnostic technologies are positively influencing the global market. Furthermore, the easy availability of numerous therapeutic drugs and extensive investments in R&D activities are expected to fuel the xerostomia (dry mouth disease) therapeutics market over the forecasted period.

Report Segmentation:

The report has been segmented the market into following categories:

Breakup by Type:

• Artificial Saliva/Saliva Substitutes
• Salivary Stimulants 

Breakup by Drug Type:

• OTC
• Prescription 

Breakup by Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy 

By Geography:

• North America (United States, Canada)
• Europe (Germany, France, United Kingdom, Italy, Spain, Others)
• Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)

List of Major Key Players:

The major players in the market are

3M Company

 Biotene (GSK plc)

 Parnell Pharmaceuticals Inc.

 Quest Products LLC

 Saliwell Ltd

 Sun Pharmaceutical Industries Limited

and West-Ward Pharmaceutical (Hikma Pharmaceuticals plc)

Key Questions Answered in the  Global Xerostomia (Dry Mouth Disease) Therapeutics Market Report
How has the global Xerostomia (Dry Mouth Disease) Therapeutics Industry performed in the past and how will it perform in the near future?
What is the impact of COVID-19 on the Global Xerostomia (Dry Mouth Disease) Therapeutics Market ?
What are the key regions in the Global Xerostomia (Dry Mouth Disease) Therapeutics industry?
What are the major driving factors and challenges in the global Xerostomia (Dry Mouth Disease) Therapeutics market?
What is the structure of the global Xerostomia (Dry Mouth Disease) Therapeutics industry and who are the leading players?
What is the degree of competition in the market?

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Services Private Limited.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800